Symposia: Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Acute Myeloid Malignancies, AML, Combination therapy, Lymphoid Leukemias, ALL, Acquired Marrow Failure Syndromes, Translational Research, Epidemiology, Bispecific Antibody Therapy, Bone Marrow Failure Syndromes, Clinical Research, Health outcomes research, Pediatric, Diseases, Therapy sequence, Immune mechanism, Biological therapies, Treatment Considerations, Real-world evidence, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, Microbiome, Emerging technologies, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous), Omics technologies
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Acute Myeloid Malignancies, AML, Combination therapy, Lymphoid Leukemias, ALL, Acquired Marrow Failure Syndromes, Translational Research, Epidemiology, Bispecific Antibody Therapy, Bone Marrow Failure Syndromes, Clinical Research, Health outcomes research, Pediatric, Diseases, Therapy sequence, Immune mechanism, Biological therapies, Treatment Considerations, Real-world evidence, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, Microbiome, Emerging technologies, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous), Omics technologies
Monday, December 9, 2024: 10:30 AM-12:00 PM
Room 6A
(San Diego Convention Center)
Moderators:
Meng Lv, MD, PhD, Peking University Institute of Hematology
and
Andrew Artz, MD, MS, City of Hope National Medical Center
Disclosures:
Artz: Astra Zeneca: Honoraria; Daichii Sankyo: Consultancy; Abbvie: Consultancy.
In this section, we have focused on refining HCT practice by precise stratification. This includes predicting outcomes through intestinal microbiome recovery, forecasting post-transplant relapse in MDS, personalizing treatment choices, determining the optimal timing for HCT in R/R AML, maintaining therapy after transplantation in FLT3+ AML, and deciding whether allo-HCT is necessary for MRD(-) CR1 ALL. We hope the ASH audience will appreciate and benefit from this section, learning how to refine prediction and therapy in HCT through emerging molecular techniques and target therapies.
10:30 AM
10:45 AM
11:00 AM
11:15 AM
11:30 AM
11:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH